Impact of paravalvular regurgitation on the mid-term outcome after transcatheter and surgical aortic valve replacement

Teemu Laakso; Mika Laine; Noriaki Moriyama; Sebastian Dahlbacka; Juhani Airaksinen; Marko Virtanen; Annastiina Husso; Tuomas Tauriainen; Matti Niemelä; Timo Mäkikallio; Antti Valtola; Markku Eskola; Tatu Juvonen; Fausto Biancari; Peter Raivio

doi:10.1093/ejcts/ezaa254

Impact of paravalvular regurgitation on the mid-term outcome after transcatheter and surgical aortic valve replacement

Eur J Cardiothorac Surg. 2020 Dec 1;58(6):1145-1152. doi: 10.1093/ejcts/ezaa254.

Authors

Teemu Laakso¹, Mika Laine¹, Noriaki Moriyama¹, Sebastian Dahlbacka¹, Juhani Airaksinen², Marko Virtanen³, Annastiina Husso⁴, Tuomas Tauriainen⁵, Matti Niemelä⁶, Timo Mäkikallio⁵, Antti Valtola⁴, Markku Eskola³, Tatu Juvonen¹, Fausto Biancari^{1

2

5}, Peter Raivio¹

Affiliations

¹ Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
² Heart Center, Turku University Hospital, Turku, Finland.
³ Heart Hospital, Tampere University Hospital and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
⁴ Heart Center, Kuopio University Hospital, Kuopio, Finland.
⁵ Research Units of Surgery, Anesthesiology and Critical Care, Oulu University Hospital and University of Oulu, Oulu, Finland.
⁶ Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.

PMID: 33057657
DOI: 10.1093/ejcts/ezaa254

Abstract

Objectives: The aim of this study was to evaluate the incidence and prognostic impact of paravalvular regurgitation (PVR) on the outcome after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) for aortic stenosis.

Methods: The nationwide FinnValve registry included data on 6463 consecutive patients who underwent TAVR (n = 2130) or SAVR (n = 4333) with a bioprosthesis for the treatment of aortic stenosis during 2008-2017. The impact of PVR at discharge after TAVR and SAVR on 4-year mortality was herein investigated.

Results: The rate of mild PVR was 21.7% after TAVR and 5.2% after SAVR. The rate of moderate-to-severe PVR was 3.7% after TAVR and 0.7% after SAVR. After TAVR, 4-year survival was 69.0% in patients with none-to-trace PVR, 54.2% with mild PVR [adjusted hazard ratio (HR) 1.64, 95% confidence interval (CI) 1.35-1.99] and 48.9% with moderate-to-severe PVR (adjusted HR 1.61, 95% CI 1.10-2.35). Freedom from PVR-related reinterventions was 100% for none-to-mild PVR and 95.2% for moderate-to-severe PVR. After SAVR, mild PVR (4-year survival 78.9%; adjusted HR 1.29, 95% CI 0.93-1.78) and moderate-to-severe PVR (4-year survival 67.8%; adjusted HR 1.36, 95% CI 0.72-2.58) were associated with worse 4-year survival compared to none-to-trace PVR (4-year survival 83.7%), but the difference did not reach statistical significance in multivariable analysis. Freedom from PVR-related reinterventions was 99.5% for none-to-trace PVR patients, 97.9% for mild PVR patients and 77.0% for moderate-to-severe PVR patients.

Conclusions: This multicentre study showed that both mild and moderate-to-severe PVR were independent predictors of worse survival after TAVR. Mild and moderate-to-severe PVR are not frequent after SAVR, but tend to decrease survival also in these patients.

Clinical trial registration number: ClinicalTrials.gov Identifier: NCT03385915.

Keywords: Aortic valve stenosis; Paravalvular regurgitation; Surgical aortic valve replacement; Survival; Transcatheter aortic valve replacement.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aortic Valve / surgery
Aortic Valve Stenosis* / surgery
Heart Valve Prosthesis Implantation* / adverse effects
Heart Valve Prosthesis*
Humans
Risk Factors
Severity of Illness Index
Transcatheter Aortic Valve Replacement* / adverse effects
Treatment Outcome

Associated data

ClinicalTrials.gov/NCT03385915